Clinical data | |
---|---|
Trade names | Tebron |
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C3H3BrF4 |
Molar mass | 194.955 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
Halopropane (synonym FHD-3, trade name Tebron) is a halocarbon drug which was investigated as an inhalational anesthetic but was never marketed. Its clinical development was terminated due to a high incidence of cardiac arrhythmias in patients, similarly to the cases of teflurane and norflurane.
See also
References
- Webster NR, Galley HF (22 August 2013). Landmark Papers in Anaesthesia. OUP Oxford. pp. 70–. ISBN 978-0-19-163319-5.
- Acta anaesthesiologica Belgica. Acta Medica Belgica. 1974.
- Klein SL (1993). A glossary of anesthesia and related terminology. Springer-Verlag. ISBN 978-0-387-97831-4.
- Catcott EJ, Smithcors JF (1973). Progress in canine practice. American Veterinary Publications.
General anesthetics (N01A) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Inhalational | |||||||||||||||
Injection |
| ||||||||||||||
|
This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it. |